In clinical trials

Digestive & weight

Retatrutide

Evidence

Phase 3 trials underway

Class

GIP, GLP-1 and glucagon receptor agonist

/

Retatrutide

KEY TAKEAWAY

Retatrutide is an investigational peptide that acts on three receptors: GIP, GLP-1 and glucagon. In a phase 2 trial, adults with obesity lost up to about 24% of their body weight over 48 weeks. It is not approved and larger trials are still running.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

An investigational triple-hormone receptor agonist

Studied for

Obesity and type 2 diabetes, in phase 3 trials

Key fact

Up to about 24% weight loss at 48 weeks in a phase 2 trial

Route

Weekly injection (investigational)

Evidence strength

Phase 3 trials underway

What it is

What it is

Retatrutide is a once-weekly injectable peptide in development. It targets GIP, GLP-1 and glucagon receptors together.

How it works

How it works

The GIP and GLP-1 actions reduce appetite and improve blood sugar. Glucagon receptor activity may add to energy use and fat metabolism in the liver.

Regulatory status

Regulatory status

Retatrutide has not been approved by the FDA or any other major regulator. It is in late-stage clinical trials. Products sold online as retatrutide are not approved medicines.

What it is used for

What it is used for

Investigated for obesity, type 2 diabetes and fatty liver disease. Use outside a clinical trial is not supported by approved labeling.

Side effects and risks

Side effects and risks

Nausea, diarrhea, vomiting and constipation were common in trials. Heart rate increases were seen in a dose-dependent way, and some people reported altered skin sensation. Long-term safety is not yet known.

Citations

Citations

Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389:514-526.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo